(Q36407273)

14 August 2017

1 reference

title

The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? (English)

1 reference

14 August 2017

0 references

T Jock Murray

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Drug Safety

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

265-274

1 reference

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Cognitive change following MPTP exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Mitoxantrone: a review of its use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Mitoxantrone treatment of multiple sclerosis: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.2.265

21 January 2018

Identifiers

DOI

10.1517/14740338.5.2.265

1 reference

14 August 2017

1 reference